(19)
(11) EP 4 816 405 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24898563.2

(22) Date of filing: 25.11.2024
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 47/68(2017.01)
C07D 403/12(2006.01)
C07K 16/32(2006.01)
A61P 35/00(2006.01)
C07D 491/22(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07K 16/30; C07K 16/2818; A61K 39/39541; A61K 2039/507; A61K 47/6857; A61K 47/6849; A61K 47/68035; A61K 47/6889
 
C-Sets:
A61K 39/39541, A61K 2300/00;
(86) International application number:
PCT/US2024/057222
(87) International publication number:
WO 2025/117403 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.11.2023 US 202363604592 P

(71) Applicant: Merck Sharp & Dohme LLC
Rahway, New Jersey 07065 (US)

(72) Inventors:
  • LUBINIECKI, Gregory Michael
    Rahway, New Jersey 07065 (US)
  • TABLANTE NUNES, Ana
    Rahway, New Jersey 07065 (US)

(74) Representative: Merck Sharp & Dohme LLC 
120 Moorgate
London EC2M 6UR
London EC2M 6UR (GB)

   


(54) COMBINATION THERAPIES FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER